country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-146187

Copy Link Print Information

Antitumor agent-69

Antitumor agent-69 (compound 12) is a potent inhibitor of protein-protein interaction between DOT1L and MLL-AF9/MLL-ENL, with K_is of 9 nM and 109 nM for AF9 and ENL, respectively. Antitumor agent-69 exhibits anticancer cellular activitiy.

For research use only. We do not sell to patients.

CAS No.: 2417651-42-2
Formula: C₄₃H₆₂N₈O₅
Molecular Weight:771.00

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (270 KB)

Antitumor agent-69 Chemical Structure

CAS No.: 2417651-42-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Histone Methyltransferase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
K562	IC₅₀	59 μM Compound: 12	Anticancer activity against human K562 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method Anticancer activity against human K562 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method	[PMID: 35612819]
KOPN-8	IC₅₀	0.1 μM Compound: 12	Anticancer activity against human KOPN-8 cells harbouring MLL-ENL assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method Anticancer activity against human KOPN-8 cells harbouring MLL-ENL assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method	[PMID: 35612819]
MOLM-13	IC₅₀	0.07 μM Compound: 12	Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method	[PMID: 35612819]
MOLM-13	IC₅₀	167 nM Compound: 12	Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 7 days measured by CCK-8 kit method Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 7 days measured by CCK-8 kit method	[PMID: 35612819]
MOLM-13	IC₅₀	382 nM Compound: 12	Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 6 days measured by CCK-8 kit method Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 6 days measured by CCK-8 kit method	[PMID: 35612819]
MOLM-13	IC₅₀	44 nM Compound: 12	Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 9 days measured by CCK-8 kit method Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 9 days measured by CCK-8 kit method	[PMID: 35612819]
MOLM-13	IC₅₀	703 nM Compound: 12	Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 5 days measured by CCK-8 kit method Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 5 days measured by CCK-8 kit method	[PMID: 35612819]
MOLM-13	IC₅₀	972 nM Compound: 12	Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 4 days measured by CCK-8 kit method Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 4 days measured by CCK-8 kit method	[PMID: 35612819]
MV4-11	IC₅₀	0.22 μM Compound: 12	Anticancer activity against human MV4-11 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method Anticancer activity against human MV4-11 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method	[PMID: 35612819]
RS4-11	IC₅₀	0.24 μM Compound: 12	Anticancer activity against human RS4-11 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method Anticancer activity against human RS4-11 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method	[PMID: 35612819]

Chemical Information

CAS No. 2417651-42-2
Molecular Weight 771.00
Formula C₄₃H₆₂N₈O₅
SMILES

O=C([C@H]1N(CCC1)C(CCC(C)C)=O)N[C@@H](C(C)C)C(N[C@@H](CNC)C(N[C@@H](CC2CCCC2)C(N[C@H](C3=NC4=CC=CC(C5=CC=CC=C5)=C4N3)C)=O)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Yuan Y, et, al. Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL. J Med Chem. 2022 Jun 9;65(11):7770-7785. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Antitumor agent-69

All Histone Methyltransferase Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

Antitumor agent-69 Related Classifications

HY-146187 Related Classifications